521-78-8
基本信息
surmontilmaleate
Einecs 208-318-3
trimepriminemaleate
TRIMIPRAMINE MALEATE
TRIMIPRAMINEMALEATE,BP
Trimeprimine Monomaleat
trimipramineacidmaleate
trimepriminemonomaleate
TRIMIPRAMINE MALEATE SALT
物理化学性质
| 熔点 | 141-143°C |
| 闪点 | 11 °C |
| 储存条件 | 2-8°C |
| 溶解度 | 氯仿：可溶,50mg/ml，透明，无色至淡黄色 |
| 形态 | powder |
| 颜色 | white |
| EPA化学物质信息 | Trimipramine maleate (521-78-8) |
安全数据
| 危险性符号(GHS) |   GHS07,GHS08 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335-H361 |
| 防范说明 | P202-P261-P301+P312-P302+P352-P305+P351+P338-P308+P313 |
| 危险品标志 | Xn,T,F |
| 危险类别码 | 22-36/37/38-63-36/38-23/25-39/23/24/25-23/24/25-11 |
| 安全说明 | 26-36-45-33-24-16-7-36/37 |
| 危险品运输编号 | 3249 |
| WGK Germany | 3 |
| RTECS号 | HN9260000 |
| 危险等级 | 6.1(b) |
| 包装类别 | III |
| 海关编码 | 2933996100 |
图谱信息
马来酸三甲丙咪嗪(521-78-8)质谱(MS)马来酸三甲丙咪嗪(521-78-8)核磁图(1HNMR)马来酸三甲丙咪嗪(521-78-8)核磁图(13CNMR)马来酸三甲丙咪嗪(521-78-8)红外图谱(IR1)马来酸三甲丙咪嗪(521-78-8)红外图谱(IR2)马来酸三甲丙咪嗪价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | HY-B1213 | 马来酸三甲丙咪嗪 Trimipramine maleate | 521-78-8 | 100mg | 500元 |
| 2024/11/08 | HY-B1213 | 马来酸三甲丙咪嗪 Trimipramine maleate | 521-78-8 | 10mM * 1mLin DMSO | 550元 |
常见问题列表
|
5-HT 1C Receptor 6.39 (pKi) |
5-HT 2 Receptor 8.10 (pKi) |
sPLA2 4.66 (pKi) |
Trimipramine displays much higher affinity for 5-HT 2 than for 5-HT 1C receptors.
The chronic administration of Trimipramine (5 mg/kg/day), as delivered by the osmotic minipump in 14 days produce significant increases in the regional concentration of 5-HT. The increases are highest in the frontal cortex and the hippocampus, followed by the olfactory tubercles and the hypothalamus. The Trimipramine treatment also produces marked increases in brain 5-HIAA concentrations ranging from 63% in the hippocampus to 25% in the nucleus accumbens with intermediate values for the hypothalamus, olfactory tubercles, frontal cortex and nucleus accumbens. Trimipramine treatment produces significant increases in DA concentrations in the nucleus accumbens, striaturn, and olfactory tubercles reaching 43, 21 and 11% respectively. Chronic administration of Trimipramine produces a marked reduction in the number of frontal cortex 5-HT 2 and striatal DA D 2 receptors. The chronic administration of Trimipramine produces an increase in the brain regional level of monoamines and metabolites indicating a greater synthesis rate for DA and 5-HT coinciding with an adaptive down regulation of 5-HT 2 and DA D 2 receptors.